Pfizer wins bid to invalidate 2 GSK patents relating to RSV vaccine
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-10-09 09:03 GMT | Update On 2024-10-09 09:03 GMT
London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held by GlaxoSmithKline (GSK) that are related to a vaccine for respiratory syncytial virus (RSV).
The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV, which typically causes cold-like symptoms but is also a leading cause of pneumonia in toddlers and older adults.
According to Reuters, GSK separately sued Pfizer in the United States last year, alleging Pfizer's vaccine violates GSK's patent rights in its RSV shot Arexvy.
A GSK spokesperson said the ruling "has no impact on our ability to launch and market Arexvy anywhere in the world, including in the UK".
"We continue to believe our patents are valid and infringed by Pfizer and will seek to appeal this decision," the spokesperson added.
Pfizer welcomed the court's decision.
"Pfizer is pleased with the decision of the UK High Court finding certain GSK patents concerning RSV-related technology both invalid and not infringed," a spokesperson said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.